Key result
Dabigatran had lower unadjusted persistence than warfarin, but the difference was not significant after adjusting for covariates including out-of-pocket costs.
Why the study?
Does dabigatran improve medication persistence compared to warfarin in patients with newly diagnosed nonvalvular atrial fibrillation?
Cohort (n=2,050)
Does dabigatran improve medication persistence compared to warfarin in patients with newly diagnosed nonvalvular atrial fibrillation?
After adjusting for sociodemographics and out-of-pocket costs, medication persistence does not significantly differ between new users of dabigatran and warfarin in patients with nonvalvular atrial fibrillation.
Answers are grounded in this paper and cite their sources.
No adjusted persistence difference; leaves open whether costs drive real-world gaps in new nonvalvular AF.
Factors influencing differences in persistence between dabigatran and warfarin in patients with nonvalvular atrial fibrillation (NVAF) remain unclear. AIM: Compare differences in persistence between new dabigatran and warfarin users in patients newly diagnosed with NVAF, adjusting for sociodemographics, clinical characteristics, patient out-of-pocket cost and other covariates. METHODS: A retrospective matched-cohort study was conducted using a US claims database of Medicare and commercially insured patients with NVAF aged≥ 18 years. Persistence and monthly out-of-pocket costs for dabigatran or warfarin were calculated and adjusted for covariates using Cox proportional hazard models. RESULTS & CONCLUSION: Unadjusted persistence was significantly lower among dabigatran users (n = 1025) compared with matched warfarin users (38 vs 46%). Adjusting for covariates rendered this difference insignificant (hazard ratio = 0.930).
No takes yet. Share an insight, caveat, or question.
Annavarapu et al. (2018) conducted a cohort in nonvalvular atrial fibrillation (n=2,050). Dabigatran vs. Warfarin was evaluated on Medication persistence (HR 0.930). Dabigatran had lower unadjusted persistence than warfarin, but the difference was not significant after adjusting for covariates including out-of-pocket costs.
Synapse has enriched 10 related papers. Consider them for comparative context: